Literature DB >> 3756355

Treatment results of nine patients with Burkitt's lymphoma.

B Anger, D Bunjes, F Carbonell, E Kurrle, H Heimpel.   

Abstract

From 6/79 until 2/86, 9 patients (median age 39) with Burkitt's lymphoma were treated. Stage D disease was seen in 7 cases, stage C in two and stage A in one. The main symptom was abdominal pain or a rapidly progressing abdominal tumor. Three patients had bone marrow involvement and two had a Burkitt's leukemia. Three had typical chromosomal aberrations. Therapy consisted of a variety of chemotherapy regimens plus additional radiotherapy and/or bulk surgery. Two patients achieved complete remissions (of 6 and 20+ months duration), and 4 partial remissions were obtained. The remaining patients had either progressive, drug resistant disease or died early. One patient is currently alive and in complete remission at 20+ months. A second patient is alive at 20+ months in partial remission with traces of IgM-paraprotein still detectable. The main causes of death were tumor-lysis syndrome (4 patients) and therapy related sepsis with progressive tumor (3 patients). This poor outcome is probably due to a high proportion of high-risk patients and suboptimal therapy for this rapidly proliferating tumor.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3756355     DOI: 10.1007/bf00320885

Source DB:  PubMed          Journal:  Blut        ISSN: 0006-5242


  15 in total

1.  The Epstein-Barr virus and neoplasia.

Authors:  G Klein
Journal:  N Engl J Med       Date:  1975-12-25       Impact factor: 91.245

2.  Cure of Burkitt's lymphoma. Ten-year follow-up of 157 Ugandan patients.

Authors:  J L Ziegler; I T Magrath; C L Olweny
Journal:  Lancet       Date:  1979-11-03       Impact factor: 79.321

3.  Treatment results of 54 American patients with Burkitt's lymphoma are similar to the African experience.

Authors:  J L Ziegler
Journal:  N Engl J Med       Date:  1977-07-14       Impact factor: 91.245

Review 4.  The relationship between Epstein-Barr virus and lymphoma.

Authors:  A G Bird; S Britton
Journal:  Semin Hematol       Date:  1982-10       Impact factor: 3.851

5.  An effective therapy for both undifferentiated (including Burkitt's) lymphomas and lymphoblastic lymphomas in children and young adults.

Authors:  I T Magrath; C Janus; B K Edwards; R Spiegel; E S Jaffe; C W Berard; J Miliauskas; K Morris; R Barnwell
Journal:  Blood       Date:  1984-05       Impact factor: 22.113

6.  High-resolution analysis of chromosome markers in Burkitt lymphoma cell lines.

Authors:  S Zhang; L Zech; G Klein
Journal:  Int J Cancer       Date:  1982-02-15       Impact factor: 7.396

7.  Prognostic factors in Burkitt's lymphoma: importance of total tumor burden.

Authors:  I Magrath; Y J Lee; T Anderson; W Henle; J Ziegler; R Simon; P Schein
Journal:  Cancer       Date:  1980-03-15       Impact factor: 6.860

8.  Cytogenetic studies on Burkitt's lymphoma-leukemia.

Authors:  R Berger; A Bernheim
Journal:  Cancer Genet Cytogenet       Date:  1982-11

9.  Effective treatment of lymphomas of Burkitt's type and B-ALL in adults.

Authors:  H W Pees; H J Riehm; J Schwamborn
Journal:  Blut       Date:  1985-04

10.  [BFM study 1981/83 of the treatment of highly malignant non-Hodgkin's lymphoma in children: results of therapy stratified according to histologic immunological type and clinical stage].

Authors:  S Müller-Weihrich; J Beck; G Henze; A Jobke; B Kornhuber; F Lampert; R Ludwig; G Prindull; G Schellong; H J Spaar
Journal:  Klin Padiatr       Date:  1984 May-Jun       Impact factor: 1.349

View more
  1 in total

1.  The BFM-protocol for HIV-negative Burkitt's lymphomas and L3 ALL in adult patients: a high chance for cure.

Authors:  H W Pees; H Radtke; J Schwamborn; N Graf
Journal:  Ann Hematol       Date:  1992-11       Impact factor: 3.673

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.